SCHEMBL3496044

SCHEMBL3496044

CN(CCOc1ccc(C[C@H](N)C(=O)Oc2ccccc2C(=O)c2ccccc2)cc1)c1ccccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 18/20 0.64
PPARA Q07869 3/20 0.64
KMT2A Q03164 2/20 0.64
MAPT P10636 2/20 0.64
MEN1 O00255 1/20 0.64
GMNN O75496 1/20 0.64
EGFR P00533 1/20 0.64
LMNA P02545 1/20 0.64
CYP3A4 P08684 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
ADRB3 P13945 1/20 0.64
TSHR P16473 1/20 0.64
ADRA2B P18089 1/20 0.64
NFKB1 P19838 1/20 0.64
TACR2 P21452 1/20 0.64
SLC6A2 P23975 1/20 0.64
TBXAS1 P24557 1/20 0.64
ADORA2A P29274 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7922668 0.82 PPARG (0.62) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7926636 0.81 PPARG (0.54) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7708299 0.79 PPARG (0.87) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7923265 0.79 PPARG (0.87) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7923269 0.79 PPARG (0.87) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7708298 0.78 PPARG (1.00) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL7708296 0.78 PPARG (1.00) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL2786564 0.78 PPARG (1.00) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL2642975 0.78 PPARG (1.00) PPARGPPARAKMT2AMAPTMEN1
SCHEMBL9390256 0.78 PPARG (0.66) PPARGPPARAKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236819-B2 Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-07 US disclosed
US-20100105728-A1 DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES LAGU BHARAT 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105728-A1 DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES NR1H2, RXRA, NR1H3 PPARG 25/4885PPARA 28/4885KMT2A 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.